Scott Chappel, a serial entrepreneur, has joined iTeos Therapeutics SA as chief scientific officer to help the Belgium-based company develop its portfolio of products targeting the tumour microenvironment. Prior to joining iTeos, Dr Chappel was a founder and chief technology officer of Surface Oncology Inc where he oversaw the generation and manufacture of antibodies targeting the microenvironment. He was also a founder and chief scientific officer of Arteaus Therapeutics, now part of Eli Lilly and Company, and an executive of Tokai Pharmaceuticals, now Novus Therapeutics Inc. He received a PhD in medicine from the University of Maryland School of Medicine and a BS in biology from Pennsylvania State University, both in the US.
iTeos announced the appointment on 3 July 2018.
Evernow Publishing Ltd 2018.